Integrating neuroimaging biomarkers into the multicentre, high-dose erythropoietin for asphyxia and encephalopathy (HEAL) trial: Rationale, protocol and harmonisation

Authors

Jessica L Wisnowski, Children's Hospital of Los Angeles
Robert C McKinstry, Washington University School of Medicine in St. Louis
et al

Journal

BMJ Open

Publication Date

4-22-2021

Volume

11

Issue

4

First Page

043852

Document Type

Open Access Publication

DOI

10.1136/bmjopen-2020-043852

Rights and Permissions

Wisnowski JL, Bluml S, Panigrahy A The HEAL Study Group, et alIntegrating neuroimaging biomarkers into the multicentre, high-dose erythropoietin for asphyxia and encephalopathy (HEAL) trial: rationale, protocol and harmonisationBMJ Open 2021;11:e043852. doi:10.1136/bmjopen-2020-043852 http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Published by BMJ

Recommended Citation

Wisnowski, Jessica L; McKinstry, Robert C; and et al, "Integrating neuroimaging biomarkers into the multicentre, high-dose erythropoietin for asphyxia and encephalopathy (HEAL) trial: Rationale, protocol and harmonisation." BMJ Open. 11, 4. 043852 (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10328